Cancer vaccines aim to elicit systemic immune responses against mutated or highly expressed tumor antigens, such as EGFR, EGFRvIII, NF1, TERT, PDGFRA, PTEN, RB1, IDH1, TP53, PIK3R1, and PIK3CA in gliomas [1]. This evidence concerns the gene TERT and central nervous system cancer.